Endologix, Inc. (ELGX) Set to Announce Quarterly Earnings on Tuesday
Endologix, Inc. (NASDAQ:ELGX) will announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $48.60 million for the quarter, compared to analyst estimates of $47.58 million. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. The business’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same period last year, the company earned ($0.20) EPS. On average, analysts expect Endologix to post $-0.71 EPS for the current fiscal year and $-0.54 EPS for the next fiscal year.
Shares of Endologix, Inc. (NASDAQ:ELGX) traded up 1.13% on Tuesday, reaching $5.36. The company’s stock had a trading volume of 77,240 shares. The firm has a 50 day moving average of $4.88 and a 200 day moving average of $5.13. Endologix, Inc. has a 52-week low of $4.08 and a 52-week high of $10.55. The company’s market cap is $447.21 million.
A number of analysts recently weighed in on ELGX shares. ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research upgraded Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 price objective for the company in a report on Monday, July 24th. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Endologix in a report on Monday, July 31st. Stifel Nicolaus set a $6.00 price objective on Endologix and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Canaccord Genuity restated a “hold” rating and issued a $5.00 price objective on shares of Endologix in a report on Wednesday, September 27th. Two investment analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.28.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.